Paradigm Clinical Research

08/31/2026

In a recent interview with the Association of Multisite Research Corporations (AMRC), Paradigm Clinical Research CEO Kurt Mussina discusses why traditional measures like site count, geographic reach, and enrollment experience only tell part of the story.

He shares why a site organization’s operating model – how teams work, make decisions, use technology, and support investigators – can be just as important in understanding how consistently an organization can perform.

Thank you to AMRC for featuring Kurt and helping advance this important industry conversation.

Read the full interview: https://amrc.org/spotlight/paradigms-kurt-mussina-on-rethinking-how-clinical-research-sites-are-evaluated/

07/13/2026

A meaningful milestone for the SURPASS-IPF program — achieved at our Paradigm Clinical Research site in Redding, California.

The first patient in Celea Therapeutics’ global Phase 3 SURPASS-IPF trial was dosed under the leadership of Principal Investigator Rafael Lupercio, M.D., a pulmonologist at Shasta Critical Care Specialists.

The trial is evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis through a comparison with an approved antifibrotic therapy. Dr. Lupercio highlighted the importance of the study’s active-treatment design for people living with a disease as serious and progressive as IPF.

Congratulations to Dr. Lupercio and our Redding team for the preparation, collaboration, and patient-centered ex*****on behind this accomplishment.

Read Celea Therapeutics’ announcement:
https://www.celeatx.com/news-blog/celea-therapeutics-doses-first-patient-in-global-phase-3-surpass-ipf-trial-evaluating-deupirfenidone-for-the-treatment-of-idiopathic-pulmonary-fibrosis

Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

06/19/2026

Psychedelic-assisted therapy research is an evolving area of clinical development — and the right research environment matters.

Thank you to KRCR News Channel 7 for highlighting Paradigm Clinical Research’s expanded research suite supporting psychiatric clinical trials and studies evaluating investigational psychedelic-assisted therapies.

Paradigm Clinical Research announced June 18 that it has opened a psychedelic research suite at its expanded clinical research site in Redding. The company ...

06/18/2026

We're pleased to announce the opening of a purpose-built psychedelic research suite at our expanded Redding, California site — a specialized environment designed to support psychiatric and psychedelic-assisted research studies for some of the most complex conditions in mental health, including treatment-resistant depression, PTSD, and substance use disorders.

Studies like these require far more than a standard exam room. They call for purpose-built spaces, specialized training, careful monitoring, and deep respect for the participant experience — and that's exactly what this new suite was created to deliver.

We're grateful to our teams, our partner principal investigators, and the sponsors and partners who make this work possible.

Learn more at https://paradigm-research.com/sponsors-cros/psychiatric-and-psychedelic-clinical-research/

🌐 ParadigmPays.com

06/10/2026

Paradigm Clinical Research is proud to welcome Greg Licholai, MD, to our board of directors.

Dr. Licholai brings more than three decades of leadership across clinical development, healthcare innovation, and building and scaling organizations at the highest levels of the biopharmaceutical industry. His career spans executive roles at Syneos Health, ICON plc, Moderna and Quintiles, as well as founding biotechnology companies and advising regulators shaping the future of clinical research.

As our CEO Kurt Mussina shared: "Greg understands this industry from every angle: as a physician, as an executive, as a founder, and as an advisor to the regulators who shape it. He shares our belief that consistency, reliability, and patient experience will define the next generation of clinical research, and his joining our board reflects the ambition and momentum behind where Paradigm is headed."

We couldn't agree more. Welcome, Greg!

Read the full announcement at https://paradigm-research.com/news/paradigm-clinical-research-appoints-greg-licholai-md-to-board-of-directors/

06/08/2026

That's a wrap on the American Diabetes Association Scientific Sessions in New Orleans.

From late-breaking incretin and obesity trials to advances in beta cell replacement, diabetes technology, and precision medicine, the science on display this year was a powerful reminder of why we do what we do at Paradigm. We came away energized by new connections and the shared commitment to improving outcomes for people living with diabetes.

If you or a loved one is interested in learning more about clinical trials for diabetes, weight loss, and related metabolic diseases led by board-certified physicians, please visit ParadigmPays.com.

06/08/2026

Please join us in welcoming Dr. Lindie Borton, board-certified dermatologist, as a Partner Principal Investigator based in Boise.

Long-standing community physicians often bring something uniquely valuable to clinical research: deep patient relationships, continuity of care, and decades of real-world clinical perspective.

Dr. Borton has more than 35 years of experience in dermatology and academic medicine. She has maintained a teaching appointment with the UCSF Department of Dermatology since 1985 while building and leading dermatology practices in both Ketchum and Boise, Idaho. Today, she practices full time at Sun Valley Skin Center in Boise.

Dr. Borton earned her medical degree from the University of California San Francisco and completed both her internship in internal medicine and dermatology residency through UCSF and Mt. Zion Medical Center.

Her combination of academic involvement, long-term patient care, and ongoing engagement with advances in dermatology brings important perspective to clinical research at the community level.

05/21/2026

Today, on Clinical Trials Day, we recognize the people who make clinical research possible. From patient recruitment and study coordination to operations, administration, and site leadership, every member of our team plays an important role in advancing research and helping bring new treatment options to patients.

At Paradigm Clinical Research, our employees are at the center of everything we do. Their expertise, compassion, collaboration, and commitment to excellence help create meaningful patient experiences and support the successful ex*****on of clinical trials across our communities.

To our entire team: thank you for the work you do each day and for the impact you make on patients, research, and the future of medicine. We are proud to celebrate you today and every day!

05/21/2026

Celebrating Clinical Trials Day at our Redding, CA location!

Today’s celebration went beyond the clinic into a parking lot party hosted by our Redding team — bringing together patients, families, and the broader community for a blood drive, tacos, games, music, and time to connect.

Proud to be part of a community that shows up for each other!